Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup

Echtay, Akram; Andari, Emile; Atallah, Paola; Moufarrege, Roland; Nemr, Rita

doi:10.18865/ed.27.1.45

Cited by 2 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A study conducted by Seufert J et al [ 25 ] demonstrated that switching the basal insulin to Gla-300 in basal insulin supported oral regimen improved metabolic control and treatment satisfaction with a decreased risk of symptomatic and nocturnal hypoglycemia and without weight gain. It is evident that insulin detemir implemented as an add-on therapy to OADs improved glycemic control without increased risk of hypoglycemia, adverse events or body weight compared with baseline [ 26 ].…”

Section: Currently Used Basal Insulin Analoguesmentioning

confidence: 99%

Clinical Evidence and Practice-Based Guidelines on the Utility of Basal Insulin Combined Oral Therapy (Metformin and Glimepiride) in the Current Era

Shrivastava¹,

Kesavadev

Mohan

et al. 2023

CDR

View full text Add to dashboard Cite

Background and Aim: Basal insulin combined oral therapy consisting of insulin and oral anti-diabetic drugs (OADs) is recommended for type 2 diabetes uncontrolled on OADs. There is a lack of clear evidence and recommendations on the combined use of basal insulin analogues to more than one OADs (glimepiride plus metformin) in effective control of glycemic parameters and its safety in terms of reduced hypoglycemic events, weight gain and cardiovascular risk. In this context, a group of clinical experts discussed the utility of basal insulin combined oral therapy with metformin and glimepiride in the current era. Methods: The clinical experts discussed and provided their inputs virtually. The expert panel included clinical experts comprising endocrinologists and diabetologists from India and Nepal. Results: The panel thoroughly reviewed existing literature on the subject and proposed clinical evidence and practice-based guidelines. Conclusion: These current clinical practice guidelines highlight the efficacy and safety of basal insulin combination therapy with various available basal insulins including neutral protamine hagedorn, detemir, glargine and degludec in addition to metformin and glimepiride therapy.

show abstract

Section: Currently Used Basal Insulin Analoguesmentioning

confidence: 99%

Clinical Evidence and Practice-Based Guidelines on the Utility of Basal Insulin Combined Oral Therapy (Metformin and Glimepiride) in the Current Era

Shrivastava¹,

Kesavadev

Mohan

et al. 2023

CDR

View full text Add to dashboard Cite

show abstract

“…Penurunan KGDP pada kelompok yang mendapat terapi kombinasi OAD + insulin terlihat paling besar diantara terapi lannya. Hal ini didukung oleh hasil penelitian Echtay et al, (2017) yang menunjukan ratarata KGDP pasien mengalami penurunan yang signifikan dari 213,7±60,1 mg/dL menjadi 120,3±25,7 mg/dL (p<0,0001). Penggunaan insulin yang dikombinasikan dengan OAD pada pasien DM tipe 2 dikatakan dapat meningkatkan kontrol glikemik pasien tanpa adanya peningkatan kejadian hipoglikemi dan peningkatan berat badan pada pasien.…”

Section: Perubahan Rata-rata Kgdpunclassified

Untitled

Sukarmini¹

2019

jfu

View full text Add to dashboard Cite

Retinopati diabetik (RD) merupakan komplikasi mikrovaskular DM karena adanya kerusakan pembuluh darah retina yang dapat menyebabkan kebutaan permanen. Kontrol glukosa darah yang baik terbukti mengurangi onset dan risiko perkembangan RD. penelitian ini bertujuan untuk mengetahui penggunaan obat antidiabetes pada pasien DM tipe 2 komplikasi RD dan luaran terapi dilihat dari perubahan kadar glukosa darah dan derajat RD pasien. Desain penelitian ini adalah observasional dengan pendekatan retrospektif. Data penelitian diperoleh dari rekam medis pasien DM tipe 2 komplikasi RD periode Januari 2018-Desember 2018 di RSUP Sanglah. Data derajat RD dianalisis secara deskriptif sedangkan perubahan kadar glukosa darah dianalisis secara statisik (paired t-test dan wilcoxon). Pada penelitian ini didapatkan sebanyak 29 pasien yang memenuhi kriteria inklusi dengan penggunaan obat terdiri dari insulin sebanyak 14 pasien (48,3%), OAD (oral antidiabtes drugs) sebanyak 9 pasien (31,0%) dan kombinasi OAD + insulin 6 pasien (20,7%). Rata-rata KGDP pasien menurun signifikan (p<0,05) pada penggunaan OAD, insulin, dan kombinasi OAD + insulin masing-masing sebesar 52,22±20,34; 58,86±19,29 dan 92,83±26,99 mg/dL. Rata-rata KGD2PP pasien menurun signifikan (p<0,05) pada penggunaan OAD dan insulin masing-masing sebesar 69,00±23,22 dan 79,35±31,58 mg/dL, namun pada penggunaan kombinasi OAD + insulin penurunan yang terjadi tidak signifikan (p>0,05) sebesar 67,33±49,55 mg/dL. Rata-rata HbA1c pasien menurun signifikan (p<0,05) pada penggunaan OAD, insulin dan kombinasi OAD + insulin masing-masing sebesar 1,77±0,39; 1,58±0,52 dan 1,60±0,55 %. Peningkatan derajat RD terjadi pada 5 dari 29 (17,24%) pasien. Kata kunci: Dabetes mellitus tipe 2, Retinopati diabetik, Glukosa darah, OAD, Insulin.

show abstract

Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup

Cited by 2 publications

References 32 publications

Clinical Evidence and Practice-Based Guidelines on the Utility of Basal Insulin Combined Oral Therapy (Metformin and Glimepiride) in the Current Era

Clinical Evidence and Practice-Based Guidelines on the Utility of Basal Insulin Combined Oral Therapy (Metformin and Glimepiride) in the Current Era

Untitled

Contact Info

Product

Resources

About